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Context: The association between combined oral contraceptives (OC) and the risk of myocardial
infarction (MI) has been intensively studied, and conclusions are controversial.While progestogen-
only contraceptives (POC) are commonly used worldwide, their impact on cardiovascular diseases
is poorly investigated and remains unclear.
Objective:We carried out a meta-analysis based on EMBASE- and MEDLINE-referenced literature
corresponding to OC marketed since 1960.
Methods: Eligible articles published in English language describingOCor POCuse andMI outcome
were reviewed, and relevant ones were extracted. All types of POC and route of administration
were considered.
Results: Six case-control studies were identified. The combined odds ratio showed no increase in
the MI risk with POC use (odds ratio  1.07; 95% confidence interval, 0.62–1.84). This result was
similar according to the route of administration, including implant, injectable, and oral POC.
Conclusion: Data from observational studies suggest no increase in risk of MI with POC use. How-
ever, these results are based on limited data. Further investigations are needed, especially among
women at high MI risk. (J Clin Endocrinol Metab 96: 1169–1174, 2011)
Myocardial infarction (MI) is an uncommon diseaseamong childbearing-aged women. Its annual inci-
dence is two permillion among healthywomen aged 30 to
34 yr old and rises to 20 per million between 40 to 44 yr
(1). Over the past decades, many studies have debated the
matter of combined oral contraceptives (OC) and the risk
of cardiovascular disease. While some of them failed to
show an association between OC use and MI risk (2–5),
others found an increased incidence of coronary events
among OC users (6–10). In addition, two meta-analyses
of the literature concluded that there was a higherMI risk
among women using OC (11, 12) compared with nonus-
ers. Regarding the interactionwith environmental and de-
mographical factors,MI risk amongOCusers is increased
by smoking, especially for women over 35 yr old (8).
Although the original development of OC focused on
progestogen-only products, progestogen-only contracep-
tives (POC) were introduced in family planning later than
combinedOC (13). The number of POCusers is estimated
tomore than 20million people worldwide (14), and using
progestogen-only products as a contraceptive method
may be an attractive option for women with or without
cardiovascular risk factors. Nevertheless, the occurrence
of MI related to POC has rarely been studied so far, be-
causeof the lowevent rate amongchildbearingagewomen
as well as the lack of statistical power to assess the risk.
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Based on these observations, we conducted a meta-
analysis of epidemiological studies to examine the rela-
tionship between POC use and risk of MI.
Materials and Methods
Selection of studies
We reviewed the literature published since the early sixties
after the introduction of OC. Potentially eligible articles were
identified from MEDLINE and EMBASE using the following
heading terms: “myocardial infarction,” “cardiovascular dis-
ease,” “progestogen-only pill,” “minipill,” “progestin,” “coro-
nary event,” “Provera,” and “contraceptives.” We only re-
trieved studiespublished inEnglish.Theywereall screenedbased
on their abstract. We also identified original articles by back
references from general reviews. We excluded publications
whichwerenot related to the topic, onpostmenopausal hormone
therapy, and biological studies. The selected articles were re-
viewed, andwe excludedgeneral reviews andarticles that didnot
address MI risk.
Data extraction
All relevant articles were consensually selected by the two
investigators (Z.C. andG.P.-B.).We assessed the quality of stud-
ies using a specific checklist, and we only included studies that
fully completed theses inclusion criteria (15). To be included,
cohort or case-control studies had to be controlled at least for
age.Nonfatal cases ofMIwere identifiedbasedon chest pain and
changes in electrocardiogram and/or cardiac enzyme elevation.
Fatal MI cases based on these criteria were also accepted if pa-
tients underwent a necropsy that confirmed the diagnosis. Re-
garding hormone exposure, OC users and nonusers (former
and/or never) were clearly defined. We considered all type of
POCs and delivery devices (oral, implant, or injectable). Suffi-
cient data ought to be provided to assess relative risks or odds
ratios (OR) with their 95% confidence intervals (CI).When sev-
eral articles reported results of the same study, we used the most
updated data.
Statistical analysis
For each study, we used the most adjusted OR with its 95%
CI and we estimated variance of OR from the 95% CI. We
weighted OR by the inverse of their variance to obtain a pooled
measurement of the OR. The combined OR was obtained using
both fixed effect model (16) and random effect model (17) ac-
cording to the homogeneity between studies (18). In the fixed
effect model, it is assumed that the effect is the same in all pooled
studies and that the variations observed between studies only
correspond to random measurement errors. On the contrary,
the random effect model acknowledges the fact that the vari-
ations observed between studies correspond to a combination
of a specific true effect andmeasurement errors. Homogeneity
between studies was tested using the Cochrane test. We as-
sessed publication bias graphically by using a funnel plot and
statistically by using a linear regression test of funnel plot
asymmetry. We used R statistical software package (meta)
version 2.10.1 for all analyses.
Results
The systematic retrieval process to identify eligible studies
is summarized in Fig. 1. Among the 28 selected articles, 22
were excluded because the MI risk associated with POC
use could not be assessed. These 22 excluded articles in-
cluded 14 case-control studies, two nested case-control
studies, and six cohort studies. We included six case-con-
trol studies mentioning the MI risk in relation to POC or
presenting a subgroup of women using POC (5, 10, 19–
22). There was no cohort study which met the inclusion
criteria for the meta-analysis. Characteristics of these
studies are shown in the Table 1. Three of the studies were
set-up in Europe (5, 19, 22), two in the United-States (10,
20), and one worldwide (21). Participants’ age in these
included articles ranged from 15 to 44 yr old, and cases
andcontrolswerematched for age. In all of them,MIevent
was clearly defined and diagnosed with clinical, biologi-
cal, and/or radiological tools. Twopublications dealtwith
fatal MI only (5, 19), two gave only data on nonfatal MI
(10, 21), and two studied all types ofMI (20, 22).Controls
were differentially selected from a study to the other one.
The World Health Organization (WHO) study and the
study by Rosenberg only included hospital controls (10,
21), whereasHeinemann recruited the controls from both
hospital and general population (22) and two studieswere
selected fromgeneral practice (5, 19). The number of cases
and controls ran from 127 to 592 and from 264 to 2711,
respectively. Subjects were exposed to oral POC in four
studies (5, 10, 19, 22), to oral and injectable POC in one
other (21), and to Norplant in the last one (20). In each
study, cardiovascular risk factor, including especially age,
FIG. 1. Flowchart of eligible studies. HT, postmenopausal hormone
therapy.
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smoking, hypertension, and diabetes, were taken into ac-
count for the analyses.
The pooled OR for MI event between POC users vs.
POC nonusers was 1.07 (95% CI: 0.62–1.83) (Fig. 2),
which did not reach the statistical significance. The test for
homogeneity did not underline great differences between
studies (P value 0.57). Information on progestogen type
used and its dose was not available for all studies. How-
ever, the pooled estimated OR for the MI risk associated
with oral POCusers (5, 10, 19, 21, 22) was 1.05 (95%CI:
0.60–1.85) (test for heterogeneity: P  0.55). When in-
jectable progestogen was excluded, no difference in esti-
mated OR was found. Finally, two studies provide the
information on the type of progestogen and showed no
significant increase in MI risk among users of either
Levonorgestrel implant or medroxyprogesterone acetate
injectable (8, 20).
We did not find evidence for publication bias from the
funnel plot, which showed a symmetrical distribution of
the individual study ORs around the overall OR (Fig. 3).
The linear regression test of funnel plot asymmetry was
also not significant (P  0.22).
Discussion
POC was introduced on the market after the combined
pills in 1973.While the prevalence of its use varied widely
around theworld, POCassured effective contraceptive for
millions of women. The aim of our work stood on eluci-
dating whether POC use was safe with respect to MI risk.
To our knowledge, this meta-analysis is the first assessing
the association between POC andMI risk. No significant
association was apparent between POC use and MI with
an overall OR of 1.07 (95% CI: 0.62–1.84).
This meta-analysis has several methodological limita-
tions. First, becauseof the low incidenceofMIamongyoung
women,nocohortstudywasadequatelydesignedtoevaluate
theMI risk associated with POC, and all
selected studies were case-control stud-
ies. Such studies are more susceptible to
recall bias than cohort studies.A survival
bias could also explain null findings, and
we cannot exclude an increased risk of
fatal MI associated with the first year of
POCuse. Second, themeta-analysis only
included six studies, and all individual
study OR were assessed on small popu-
lation samples. We cannot therefore ex-
clude that the absence of association be-
tweenPOCuseandMI in each studywas
attributable to a lackof statistical power.
However, the power of our meta-anal-
FIG. 2. OR and their 95% CI of MI associated with POC use from individual studies and
overall.
TABLE 1. Characteristics of studies evaluating Progestogen-only contraceptive use and the risk of myocardial
infarction
Case-control
study, year Region
Years of
study
Age
(yr) Control type
Number
of cases/
controls
No of
cases/controls
exposed to POC POC type
Event
definition
Matching or
adjustment variables
Thorogood
1991 (19)
UK 1986–1988 16–39 General practitioner 127/264 3/12 Oral Fatal MI Age and marital status
Petitti 1998
(20)
USA 1990 18–44 Population controls 307/1048 1/1 Implant All MI Age
WHO 1998
(21)
Worldwide 1989–1993 20–44 Hospital 263/809 4/14 Oral and
injectable
Nonfatal MI Age, HBP, diabetes,
smoking
Heinemann
1999 (22)
Europe 1993–1996 16–44 H and P 133/474 7/17 Oral All MI Age, HBP, diabetes,
smoking, education
Dunn 1999 (5) UK 1993–1995 16–44 General practitioner 395/1516 9/49 Oral Fatal MI Age, smoking, BMI, HBP,
diabetes, family
history of MI
Rosenberg
2001 (10)
USA 1985–1998  45 Hospital 592/2711 1/1 Oral Nonfatal MI Age, residence area,
HBP, diabetes,
smoking, BMI, high
cholesterol, family
history of MI
H, hospital; P, population controls; All, fatal and nonfatal MI; BMI, body mass index; HBP, high blood pressure.
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ysis to detect anORof two for users of POC vs. nonusers
was 95% at the 5% significance level. An OR of two is
based on the results of two previous meta-analyses re-
latingMI risk and OC (11, 12). Third, the magnitude of
the association between POC and MI could be affected
by two distinct parameters: 1) the selection of an hos-
pitalized control group—which were more likely to be
at high cardiovascular risk—could underestimate this
relationship (vs. a population control group), and 2) the
determination of POC users and nonusers varied from
0 to 3 months before the inclusion date, which could
classify a participant into one or the other category de-
pending in each study. Moreover, because of the lack of
information on dose and type of oral POC, we cannot
exclude an increased MI risk for the use of a specific
molecule. Finally, although almost all studies were con-
trolled for appropriate confounders, some important
other risk factors might be unbalanced between POC
users and nonusers, especially the healthy user charac-
teristics. Women who used contraceptives were more
likely than nonusers to be in better health and to partic-
ipate to the health maintenance and disease screenings.
This discrepancy between users and nonusers might un-
derestimate the magnitude of the association between
POC use and MI risk.
The association between MI and important cardiovas-
cular risk factors, such as high blood pressure, was shown
in two studies. The WHO study found an OR of 8.05
(95% CI: 4.89–13.3) for all MI among hypertensive
women, and POCuse did not confer an additionalMI risk
to these women (21). Moreover, the Transnational Study
confirmed that the greater MI risk related to high blood
pressure (OR 8.34, 95% CI: 3.76–18.51) was not fur-
ther increased by POC use (22). Nevertheless, these data
must be interpreted with caution, because the number of
women with a history of hypertension and POC use was
very small. POC currently remains a contraceptive option
for women with hypertension as long as it is well con-
trolled and monitored (23). Hall et al. (24) established, in
a U.S. prospective controlled study comparing women us-
ing POC for at least 6 months and matched control pop-
ulation using copper intrauterine device, that therewas no
significant rise in systolic and diastolic blood pressure. In
addition, Wilson et al. (25) determined the same results
with their Scottish population with oral and injectable
POC over a 2-yr period.
Similar data regarding smoking were reported. In the
WHO study, the adjusted OR for MI which was 4.96
(95%CI: 3.38–7.29) amongOCnonuser smokers did not
significantly rise among smokers with oral POC use.
Moreover, the Transnational Study showed an elevated
OR associated with smoking (OR  10.20, 95% CI:
5.04–20.61), which was very similar to additional oral
POC use (OR  10.41, 95% CI: 1.10–98.83).
Progestogens as a contraceptive method have been as-
sessed on lipid parameters. On one hand, lipoproteins have
beenmeasured in several studies before andafter insertionof
Norplant, andmost of these publications showeda lowering
in triglycerides, total cholesterol, and low-density lipopro-
tein concentrations.On theotherhand, lipidprofilehasbeen
studied among POC users, and data remain controversial.
While one study found that high-density lipoprotein (HDL)
cholesterol was slightly diminished or even increased (26), a
Norwegian cross-sectional survey showed that depot me-
droxyprogesterone acetate (DMPA) andall oral POCs—ex-
cept oral levonorgestrel—were linkedwith lower concentra-
tions ofHDL cholesterol comparedwith hormone nonusers
(27). In addition, this latter study exhibited that total cho-
lesterol and triglycerides were higher with oral and DMPA
use. In both studies, there was little change in the total cho-
lesterol/HDL cholesterol ratio,whichmight imply that POC
should not aggravate risk factors for atherosclerosis, but this
hypothesis still remains to be confirmed.
Numerous papers on DMPA reported a significant ele-
vationof insulin concentration comparedwithbaseline after
sequential oral glucose tolerance test (28) and iv glucose tol-
erance test (29). Despite the reduced insulinosensitivity,
most of the studies did not find any effect of POC on
glucose concentrations in lean women. Increased glu-
cose involved in heavier DMPA users or long treatment
duration users (29). Other studies also observed an in-
crease in insulin area under the curve with etonogestrel
implants after oral glucose tolerance test and in Nor-
plant users, an elevation of glucose concentrationswhich
is intensifiedwith greater implant use period and returned
to baseline after removal (30, 31). This presumption of
insulin resistance was supported by a finding of increased
free fatty acids after glucose challenge amongDMPAusers
(32). One other mechanism might be weight gain. Cross-
sectional and longitudinal studies of DMPA users gener-
ally found increasedmeanweight (33), which appeared to
be associated with changes in adipose mass (34). About
30% of implant users noted either weight gain or weight
FIG. 3. Funnel plot of the studies of POC use and MI risk.
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loss, the former being more frequent in developing coun-
tries (35, 36).
Regarding blood coagulation, POC could have no del-
eterious effect on hemostasis. Indeed, in the study byWin-
kler et al. (37), desogestrel and levonorgestrel induced a
reduction of factor VII activity and fragment 1  2 con-
centration. In addition, these progestogens had no effect
on antithrombine and protein C, whereas protein S in-
creased notably. Authors also noticed a nonsignificant de-
crease in D-dimers. Concordant results were found in a
phase III trial focusing on DMPA, which reported steady
antithrombin and factorVIIIc levels coupledwith lowered
D-dimers and C-reactive protein (CRP) (38). Decreases in
bothD-dimers andCRP support a potential reduced riskof
venous and/or arterial thrombosis. D-dimers are a marker
of procoagulant and subsequent fibrinolytic activity,
whichwas established as an indicator of venous and some-
times arterial thrombotic risk (39, 40). Likewise some
studies reported a link between high CRP levels and the
risk of MI and stroke (41, 42).
Finally, in the Transnational Study, POC users tended to
be older, had a higher body mass index, were more often
smokers,more frequently had hypertension or diabetes, and
more often had a family history disease than users of com-
bined OC (22). Some of these differences in the risk factor
profile were also observed in the WHO study, even if they
were less consistent (21). These differences in the POC char-
acteristics users between Transnational and WHO studies
could be explained by a selection bias. The latter study in-
cluded a large population from developing countries where
POCs are frequently prescribed in first line because of their
cheapness andeffectiveness.Bycontrast,womenrecruited in
the Transnational Study came mainly from industrial coun-
tries where POCs are often used as an alternative to OC for
womenwithcardiovascularriskfactors.Despite thisdiscrep-
ancy, no change in MI risk between these two studies was
noted. One explanation could be that these women were
narrowly monitored to correct these cardiovascular risk
factors.
In conclusion, this meta-analysis suggests that POC use
might be safe with respect to MI risk. However, further in-
vestigation regarding this topic is needed, especially among
womenwith cardiovascular risk factors, andPOCsmust still
be cautiously used for these women.
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